| Pair Name | Zerumbone, Paclitaxel | ||
| Phytochemical Name | Zerumbone (PubChem CID: 5470187 ) | ||
| Anticancer drug Name | Paclitaxel (PubChem CID: 36314 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Zerumbone, Paclitaxel | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->ROS-mediated oxidative stress | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CASP7 | hsa840 | |
| Up-regulation | Expression | CASP9 | hsa842 | |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| Result | The prooxidant properties of zerumbone potentially resensitize breast cancer cells to PTX by enhancing intracellular ROS-mediated oxidative stress. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Zerumbone-induced reactive oxygen species-mediated oxidative stress re-sensitizes breast cancer cells to paclitaxel. Biotechnol Appl Biochem. 2023 Feb;70(1):28-37. doi: 10.1002/bab.2326. | Click |
